Randomized Trialhigh evidence
Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial.
JAMA·August 19, 2026·PMID 42616542
Why it mattersAcute pain episodes are the leading cause of emergency visits and hospitalizations in sickle cell disease, yet no FDA-approved therapy exists. Arginine had shown promise in phase 2 trials, but this definitive trial found no benefit, preventing adoption of an ineffective treatment and redirecting efforts toward other strategies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled